Xconomy

JANUARY 11, 2019

[ Editor’s note: Ben Fidler and Sarah de Crescenzo coauthored this report.] It is here, and then it is gone. But by the time everyone staggers to the airport or back home to sleep in their own beds, the annual few days of the J.P.

Pricing 97

Pricing Conference Report Help 97

Xconomy

FEBRUARY 27, 2017

La Jolla Pharmaceutical’s experimental drug to treat a deadly blood pressure condition hit its main goal in a Phase 3 clinical trial, boosting the company’s stock price by more than 75 percent on Monday morning.

San Diego 40

San Diego Study Pricing Organization 40

Xconomy

AUGUST 11, 2016

government has ambitious plans for a long-term health study with one million Americans, and one of the world’s most powerful tech companies has a big part to play, including the storage of all the data on its “cloud” servers. It even has a price guide.). million, with potentially $72 million over five years.

PMI 40

PMI Study Google Research 40

Xconomy

DECEMBER 20, 2016

San Diego-based Acadia (NASDAQ: ACAD ) reported that patients treated in an exploratory study with its drug pimavanserin showed a statistically significant reduction in psychosis compared against a group given a placebo. Investors cheered the news, boosting Acadia’s stock price 13.6 percent to $28.88

San Diego 40

San Diego Statistics Study News 40

Xconomy

OCTOBER 28, 2016

THIS WEEK IN DRUG PRICING…. —A coalition of investors pressed drug makers to justify price increases. The group filed shareholder resolutions with 11 companies and cited a Kaiser Family Foundation poll that cited Americans’ concerns over drug prices.

Pricing 40

Pricing Conference News Study 40

Xconomy

SEPTEMBER 9, 2016

—Allergan CEO Brent Saunders criticized “egregious price takers” and pledged his own firm would practice responsible pricing to get out in front of potential legislative action that Democratic presidential candidate Hillary Clinton has been threatening.

Pricing 40

Pricing Startup News Screening 40

Xconomy

MARCH 16, 2018

Drug prices are top of mind for many patients. Some of them have to cut back on basic needs just to pay for treatments that seem to rise in price each year. The Tarrytown, NY, drugmaker plans to cut the price of its cholesterol-lowering drug alirocumab (Praluent) if it can get concessions from payers.

Pricing 59

Pricing Study San Diego Blogging 59

Xconomy

SEPTEMBER 7, 2016

Retrophin , the drug developer founded by controversial former biotech executive Martin Shkreli, has posted positive results from a midstage study for its treatment for a rare kidney disease. He licensed the drug from San Diego-based Ligand Pharmaceuticals (NASDAQ: LGND ) in March 2012. to $30 apiece. to $750 a pill.

San Diego 40

San Diego Pricing Study Journal 40

Xconomy

OCTOBER 7, 2016

—Alnylam Pharmaceuticals (NASDAQ: ALNY ) of Cambridge, MA, said that it would shelve its drug revusiran after 18 patients died in a Phase 3 study to treat the rare disease transthyretin amyloidosis. PRICE FIGHTS. With some caveats, ICER recommended lower prices. She refused to discuss Edison at the time. —The U.S.

Technical Review 77

Technical Review Study Layoffs San Diego 77

Xconomy

SEPTEMBER 2, 2016

Nobel Prize winner Roger Tsien, a UC San Diego chemist, passed away in Oregon this week. As the San Diego Union Tribune reported in 2013, Tsien (pictured) was also unafraid to shine the spotlight on what he considered suspect scientific approaches, even when espoused by legends like DNA co-discoverer James Watson. .

News 57

News San Diego Journal Technical Review 57

Xconomy

JUNE 21, 2018

The San Francisco company priced its IPO late Tuesday, selling 6.25 Eidos will use the cash to fund studies of AG10 , a drug in mid-stage testing for transthyretin (TTR) amyloidosis, a progressive and fatal condition caused by the. million shares at $17 each, which was on the high end of its projected $15 to $17 range.

Study 72

Study Startup Pricing Funding 72

Xconomy

MARCH 17, 2017

The data, from a massive study of more than 27,000 patients, come at a time when drug and healthcare prices are a top U.S. political issue, and pricey new cholesterol drugs have been a key battleground.

Study 87

Study Pricing Sales Journal 87

Xconomy

APRIL 6, 2018

The FDA didn’t smile upon a big submission of depression studies from Alkermes, while those fighting liver disease got a mixed slate of data as a big medical conference looms. There were plenty of policy and drug-price headlines, Read more » Reprints | Share: After the deals, we’ll move on to data.

Study 55

Study Pricing Conference Marketing 55

Xconomy

APRIL 21, 2017

Our own reporting focused this week on the fallout from high drug prices, with a look at the frustration of families whose children have had trouble gaining access to the first drug ever approved for the rare spinal muscular atrophy.

Study 49

Study News Pricing Google 49

Xconomy

MAY 24, 2019

Patients, doctors, family members, and drug-price watchdogs continued to wait for the expected approval of Zolgensma , a Novartis (NYSE: NVS ) gene therapy for the rare inherited disease spinal muscular atrophy. Originally developed at a children’s hospital in Ohio , Zolgensma will be a litmus test for the nascent field.

Pricing 86

Pricing Marketing Develop Development 86

Xconomy

SEPTEMBER 20, 2019

Meanwhile, try to find someone in the federal government who isn’t involved in the drug-price debate. Health concerns about vaping continue to mount, and the feds could get involved.

Pricing 61

Pricing News Capital San Diego 61

Xconomy

NOVEMBER 11, 2016

Drug company stocks got a boost with the defeat of Hillary Clinton, a vocal critic of drug prices. Will he take a softer stance on drug prices? But her near doubling of Trump (62 to 33 percent) didn’t translate into support for drug price controls. The Nitto drug is in a Phase 1b study. Now, the U.S.

Patents 87

Patents Study Pricing Research 87

Xconomy

MARCH 9, 2018

Trump administration health officials were out on the stump this week, talking tough about drug prices and healthcare value, encouraging the private sector to take the lead but letting everyone know the federal government is willing to push.

Pricing 56

Pricing Class Sales Marketing 56

Xconomy

JUNE 21, 2019

The announcement comes less than a month after Boulder, CO-based Array announced positive data from a pivotal study of its combination drug in colorectal cancer. Cancer remains one of the hottest areas for pharma deals and this week saw a big one: Pfizer’s proposed $11.4 billion buyout of Array Biopharma.

Study 58

Study San Diego Pricing Blogging 58

Xconomy

JULY 29, 2016

But the company said this week that sales of Sovaldi and Harvoni, which share a common ingredient, sofosbuvir, have slowed with fewer patients starting on the drugs and prices undercut by fierce competition from AbbVie and Merck. The study is one of several Celgene is running to try to expand the use of its blockbuster blood cancer drug.

Startup 40

Startup Study News Report 40

Xconomy

SEPTEMBER 1, 2017

billion, the price Gilead Sciences is paying for Kite Pharma and its cancer-fighting cell therapy pipeline. The far-out idea of reprogramming a patient’s immune cells to fight cancer, known as CAR-T, entered the mainstream this week, and two numbers highlight the tale. The first is $11.9

Pricing 74

Pricing Ideas San Diego Study 74

Xconomy

JULY 8, 2016

British medical journal The Lancet published a study , funded by the Bill and Melinda Gates Foundation, that showed viral hepatitis has become the seventh leading cause of death globally, up from tenth in 1990. The FDA has halted the trial , and Juno’s share price dropped 28 percent after hours on Thursday.

Pricing 52

Pricing News Journal Startup 52

Xconomy

APRIL 20, 2018

The price of drugs is certainly on a lot of minds these days, including the mind of President Trump, as he reportedly will make a. While pembrolizumab notched the headline-grabbing data, others are also working to develop options for various subsets of patients. Who will be able to afford all these options?

Pricing 52

Pricing News Report Develop 52

socalTECH

FEBRUARY 16, 2010

For this morning's interview, we talked with Noah Auerhahn , President of San Diego-based Extrabux (www.extrabux.com), an online site focused on providing consumers with comparison shopping combined with discount offers. Did you have any prior background in this, and what were you two studying? Noah, thanks for the interview.

USC 207

USC CPC Sites Startup 207

Xconomy

AUGUST 11, 2017

The FDA reported that generic drug approvals are set to hit a record ; the agency under Commissioner Scott Gottlieb has moved this summer to increase generic competition and lower the nation’s high drug prices. Meanwhile, drug-price hawks can sharpen their talons on a report this week from The New York Times and ProPublica.

Pricing 52

Pricing News Report Competition 52

Xconomy

JULY 18, 2016

In early trading Monday, Evoke’s (NASDAQ: EVOK ) stock price was down 72 percent to $3.02 Evoke’s late-stage study failed to show a significant benefit to the drug, EVK-001, versus placebo at all 41 of the sites that tested it nationally. per share as of 11:30 a.m. in New York.

Study 40

Study Sites News Research 40

Xconomy

JUNE 10, 2016

BIO president and CEO Jim Greenwood (pictured), a former Congressman-turned-lobbyist, told an audience, “We are fighting back,” and unveiled plans to put some of the blame for high drug prices on insurance companies. The new prices don’t reflect rebates and discounts.

Incubator 67

Incubator Thousand Oaks Screening Pricing 67

Xconomy

JANUARY 27, 2017

A new study showed it may take another 40 years to achieve gender diversity in life sciences. It was a wild week in biotech and on Capitol Hill. Tensions continued to mount between drugmakers and payers over the rising costs of rare disease drugs.

News 40

News Study Marketing Anthem 40

Xconomy

SEPTEMBER 9, 2016

Is this akin to a nationwide study, like the government’s precision medicine initiative ? TJ : No, it’s not a national study or clinical trial. X : You don’t think that sequencing prices will come down enough? The following is an edited, condensed version of our conversation. There are policy issues.

Geni 40

Geni Research Study Summary 40

Xconomy

AUGUST 19, 2016

Everyone is waiting until 2017, when huge studies of the drugs’ ability to prevent heart attacks and strokes start to provide data. . —The FDA last summer approved two new cholesterol fighting drugs known as PCSK9 inhibitors, but so far the market has rejected them, resulting in paltry sales.

Technical Review 40

Technical Review Patents .Net Study 40

Xconomy

SEPTEMBER 16, 2016

New documents came to light that showed the sugar industry paid for studies downplaying the ties between sugar and heart disease. Meanwhile, there was yet another twist in the ongoing Duchenne muscular dystrophy drama, more biotech buyouts, new startups, and the filing of a long anticipated IPO.

Research 40

Research Pricing News Report 40

Xconomy

AUGUST 30, 2019

You might be camping, barbecuing, or sleeping on Monday. It’s Labor Day, after all. But in Paris, this cardiologist will be in a conference center, walking an audience through a slide deck packed with Phase 3 data for a new cholesterol-lowering drug, inclisiran. Inclisiran’s owner, the Medicines Co.,

Slides 80

Slides Conference Venture Capital San Diego 80

Tech Zulu Event

NOVEMBER 17, 2009

This is a paid event and will cost you $20 for the discounted online price and $40 at the door. So get the online price here ( [link] ). Fellow at the University of California Center for the Study of Democracy and an Expert Blogger for Fast Company. The hashtag is #SCASN. Gregory Ferenstein, Fast Company Magazine.

Social Media 40

Social Media Southern California Media Orange County 40

Xconomy

JUNE 28, 2019

It was a busy week. If we had to choose a theme, it was all about getting together. Two huge drug companies, AbbVie and Allergan, said they’d be better as one. Two more huge drug companies, Celgene and Bristol-Myers Squibb, learned they would have to leave a big product behind if they want to merge.

Product 65

Product Company Companies San Diego 65

Xconomy

NOVEMBER 4, 2016

The Mayo Clinic cardiologist behind the report published a study earlier this year about long QT misdiagnosis leading to improper defibrillator implants. Its owner Pfizer (NYSE: PFE ) shelved it this week , citing poor Phase 3 data and pricing pressures on the two approved PCSK9 drugs. Pfizer also reported worse-than-expected earnings.

Research 40

Research Report Pricing Journal 40

Xconomy

AUGUST 12, 2016

Lilly will continue the study, but the news puts distance between abemaciclib and two similar, rival cancer drugs from Pfizer (palbociclib (Ibrance)) and Novartis (ribociclib)). Both Pfizer and Novartis stopped Phase 3 trials of their drugs early because they were clearly benefitting breast cancer patients. . In the U.S.,

Google 40

Google Technical Review News Research 40

Xconomy

JULY 18, 2016

Exact Sciences’ share price fell from a peak above $30 to below $8 on the USPSTF announcement. Better to study the test in a high-risk population more likely to benefit before exposing the general population to a test with poorly understood performance.

Screening 40

Screening Sample Tool Study 40